following a full submission:
brentuximab vedotin (Adcetris®) is accepted for restricted use within NHSScotland.
Indication under review: The treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
SMC restriction: for the treatment of patients with advanced CTCL, defined as mycosis fungoides stage IIB and above, primary cutaneous anaplastic large cell lymphoma or Sézary Syndrome.
In an open-label, phase III study in patients with previously treated CD30+ CTCL, the objective response rate maintained for at least four months was significantly higher in patients who received brentuximab vedotin than physician’s choice of one of two treatments.
This advice applies only in the context of an approved NHSScotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
- Medicine name:
- brentuximab (Adcetris)
- SMC ID:
For the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 13 January 2020